Azenta US Inc.

Azenta US Inc., doing business as Brooks Life Sciences Inc., is a subsidiary of Azenta, Inc. (Burlington, Massachusetts) that supplies genomic sequencing services, biorepository management, sample preservation equipment, and laboratory information systems to the federal government as a prime contractor on 89% of recent awards and as a subcontractor on grant and contract work. The company operates from Indianapolis, Indiana and competes on a full-and-open basis across the federal market without set-aside designations on the vast majority of recent work.

Azenta's federal footprint centers on life sciences research support. The company delivers RNA and DNA sequencing (whole exome, whole genome, transcriptome, and single-cell analysis), sample extraction and library preparation, cryogenic storage system maintenance and service, freezer management software (FreezerPro, LIMFINITY, Biobank Pro), cell isolation services, and biorepository logistics. Representative prime contracts include a $35 million definitive contract with the National Cancer Institute (award date December 2, 2024) for molecular characterization of childhood and adolescent cancers under the Childhood Cancer Data Initiative through December 2029; a $2.01 million nitrostore maintenance and service contract with Veterans Integrated Service Network 4 (award date December 7, 2021) for the VA Boston Healthcare System's Jamaica Plain biorepository through December 2026; and an $804 thousand on-site biorepository support services contract with the Defense Health Agency's Walter Reed Army Institute of Research (award date September 27, 2021). Azenta also holds three active indefinite-delivery/indefinite-quantity vehicles: a $337,920 IDIQ with the USDA Agricultural Research Service for DNA sequencing services through September 2028, a $150,000 IDIQ with the Office of Acquisitions and Grants for RNA extraction and sequencing through April 2028, and a $10 million single-award blanket purchase agreement with the National Institute of Environmental Health Sciences for biological materials and laboratory testing services through August 2026.

Customer concentration is anchored by the Department of Veterans Affairs and the National Institutes of Health. The Veterans Integrated Service Network 4 represents the single largest customer by potential value (10 awards, $109.6 million combined), driven primarily by the multiyear nitrostore maintenance contract. The National Cancer Institute contributes $87.2 million in potential value across five awards. The National Institute of Allergy and Infectious Diseases leads by award count (23 awards, $448 thousand combined value), with the National Human Genome Research Institute and National Institute of Environmental Health Sciences rounding out the top five customer agencies. Together, these five agencies account for 43% of all awards by count and 93% by potential value, reflecting deep penetration in NIH institute procurement and VA biorepository operations.

Azenta operates primarily as a prime contractor across its footprint. The vendor subcontracts to Arete Associates on DNA extraction and 16S library preparation work under federal research grants managed by Arete, and previously subcontracted sample storage services to Modernatx, Inc. on mRNA vaccine development. The company also appears as a biorepository subrecipient under grants managed by Benaroya Research Institute at Virginia Mason for the Immune Tolerance Network, providing PBMC processing, cell isolation, and sample storage and management services across multiple award dates from 2024 through 2026. Across SCI-reportable prime contracts (those exceeding the $150,000 threshold), Azenta reported $456 thousand in invoiced revenue in FY2024 and deployed zero FTEs on these contracts; the SCI dataset is a narrow view covering only service contracts above the reporting threshold and excludes the substantial goods and equipment sales that dominate Azenta's federal footprint.

Activity has moderated in the past two years after peaking in 2023. The vendor recorded 25 awards in 2022, 35 in 2023, 28 in 2024, 21 in 2025, and 6 through early July 2026. Fourteen awards (combined potential value $3.4 million) face ultimate completion within the next twenty-four months and represent recompete exposure, primarily smaller purchase orders rather than the multiyear vehicle or large definitive contracts that anchor the portfolio. The majority of awards are purchase orders (firm fixed price) and delivery orders under the IDIQ and BPA vehicles, with no small business set-asides applied. NAICS concentration reflects the company's life sciences focus: Testing Laboratories and Services (28 awards), Research and Development in the Physical, Engineering, and Life Sciences (25 awards), and Research and Development in Biotechnology (15 awards) dominate the portfolio.